

## Vortioxetine D8

## Chemical Properties


CAS No. : 2140316-62-5

Formula: C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>S

Molecular Weight: 306.5

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Vortioxetine-D8 is a deuterium-labeled Vortioxetine (TMSM-3548), a compound that inhibits 5-HT <sub>1A</sub> , 5-HT <sub>1B</sub> , 5-HT <sub>3A</sub> , 5-HT <sub>7</sub> receptors and SERT with [K <sub>i</sub> : 15 nM, 33 nM, 3.7 nM, 19 nM, and 1.6 nM, respectively].
Targets(IC <sub>50</sub> )	5-HT Receptor, Serotonin Transporter

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.2626 mL	16.3132 mL	32.6264 mL
5 mM	0.6525 mL	3.2626 mL	6.5253 mL
10 mM	0.3263 mL	1.6313 mL	3.2626 mL
50 mM	0.0653 mL	0.3263 mL	0.6525 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Bang-Andersen B, Ruhland T, Jørgensen M, Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. *J Med Chem*. 2011 May 12;54(9):3206-21.

Guilloux JP, Mendez-David I, Pehrson A, Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. *Neuropharmacology*. 2013 May 28;73C:147-159.

Theunissen EL, Street D, Højer AM, A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. *Clin Pharmacol Ther*. 2013 Jun;93(6):493-501.

Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. *Eur Neuropsychopharmacol*. 2012 Dec;22(12):858-66.

Mørk A, Pehrson A, Brennum LT, Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. *J Pharmacol Exp Ther*. 2012 Mar;340(3):666-75.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481